There was no statistically significant difference in the risk of serious infections between JAK inhibitors vs TNF antagonists (pooled HR, 1.05 [95% CI, 0.97-1.13]), with low heterogeneity (I2 = 20.4%) (Figure 1). The gene discussed is TNF; the disease is infection.